Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

SCHOTT Assists the Pharmaceutical Industry on Tracking Pharmaceutical Tubing

Published: Thursday, January 23, 2014
Last Updated: Thursday, January 23, 2014
Bookmark and Share
Company issues its 1 millionth certificate for its FIOLAX® glass tubing.

SCHOTT is supporting the pharmaceutical industry in its efforts to track the tubing used to produce pharmaceutical packaging made of glass. The company issued its 1 millionth certificate for its FIOLAX® glass tubing just recently.

These certificates help to identify the products shipped as tubing that are subsequently processed into pharmaceutical packaging, vials or syringes, for example.

They contain more detailed information on the dimensional quality and the quality of the glass. This enables pharmaceutical companies to track their packaging all the way back to the raw material “glass tubing,” if necessary.

Traceability is currently one of the most pressing issues for the pharmaceutical industry. It is closely related to more stringent requirements for quality and safety in manufacturing, shipping and administering medicines. Packaging is thus an integral part of all safety considerations.

SCHOTT became the first company in the industry to allow for all of the pharmaceutical tubing it manufactures to be identified back in 1999. The certificates are applied to the pallet in a clearly visible position and enable customers to inspect incoming shipments more easily because they contain plenty of detailed information.

One part of the certificate can be detached and stored for documentation purposes and used to perform subsequent tracking & tracing inside the e-commerce portal.

SCHOTT’s certificates can be distinguished from the certificates that its competitors use mainly in terms of their great depth of detail and clarity. Besides a description of the product that includes an exact definition of all of the characteristics of importance to the customer, they also contain highly detailed specifications on tolerances.

“In other words, we offer our customers the highest possible transparency and reliable quality,” concludes Jürgen Achatz, Global Sales Director for Pharmaceutical Tubing at SCHOTT.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SCHOTT Launches New Center of Excellence for RTU Pharma Packaging
Initiative will more closely tie together SCHOTT’s experts and pharma partners as production of adaptiQ® ready-to-use vials commences.
Saturday, October 24, 2015
Scientific News
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!